Glaucoma Trial, Recruiting NCT06963684 Sponsor: Twin Cities Eye Consultants Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT06963684
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 40 years or older, of any gender
  • People who have been diagnosed in both eyes with either high eye pressure (ocular hypertension), suspected glaucoma, or mild open-angle glaucoma, as defined by the American Academy of Ophthalmology guidelines
  • People who are not currently using any eye pressure-lowering medications, and whose eye pressure in each eye measures between 21 and 35 mmHg, with the two eyes measuring within 3 mmHg of each other
  • People with vision of 20/50 or better (with correction if needed)
  • People who are able to read and understand the study requirements and sign a written consent form
  • People who are willing to follow all study instructions and attend all scheduled check-up appointments over 12 months

Who may not be able to join:

  • People where a specific part of the eye (the scleral spur, located in the drainage angle) cannot be clearly seen during a standard eye examination called gonioscopy
  • People with certain types of glaucoma other than mild open-angle glaucoma, such as glaucoma present from birth, angle-closure glaucoma, or glaucoma caused by other eye conditions (confirm with trial site for the full list)
  • People currently taking any oral or eye-drop medications to lower eye pressure
  • People who have had any previous eye surgery, except for cataract surgery performed at least 2 years before joining the trial (YAG capsulotomy is also accepted if performed at least 60 days before joining)
  • People with significant eye conditions other than cataracts or glaucoma, such as advanced macular degeneration or proliferative diabetic retinopathy
  • People who have had a significant eye infection or inflammation within the 6 months before screening
  • People who have had a corneal transplant, or who have a significant corneal condition such as advanced Fuchs' dystrophy
  • People whose eye media (the clear parts of the eye) are too cloudy to allow a clear view of internal eye structures
  • People with an uncontrolled health condition that the trial doctor considers a risk to their safety or that may prevent them from completing all study visits
  • People who have participated in another clinical trial involving a drug or device within the past 30 days
  • Women who are pregnant or breastfeeding, or women of childbearing age who are not using a medically accepted form of contraception

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: George R Wandling, MD, Twin Cities Eye Consultants - Partner

Phone: 612-999-2020

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Twin Cities Eye Consultants
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Mean Decrease in Intraocular Pressure (IOP) from Baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov